موانع موجود در شروع به موقع درمان ترومبولیتیک در بیماران مبتلا به سکته مغزی
Authors
Abstract:
Background and purpose: The new thrombolytic agents have opened a new horizon in the treatment of patients with stroke. However, the contraindication and delay in beginning of the drug have caused serious obstacles to apply this therapy. In this study we verified these obstacles in early beginning of thrombolytic treatment. Materials and methods: In this cross sectional study, we investigated the patients with stroke attending Tehran Imam Hossain hospital from June 2010 to September 2011. The data including demographic features, financial status, previous medical history, and time interval were obtained using a questionnaire. The data was then analyzed in SPSS ver.18 applying Student’s t-tests and Chi-square. Results: Of 171 subjects, 151 were investigated. The mean age of the patients was 59.7 years and they were 97(64.2%) male. The main barriers to delivery of thrombolytic therapy were losing the golden time (70.3%), drug contraindication (20.9%), absence of intensive care bed (5.4%), and financial problems (3.4%). The average time from patient arrival time in emergency department to the time of physician’s visit, performing brain CT scan, neurology consultation and making the final decision were 11, 112, 211 and 320 minutes, respectively. Conclusion: The main obstacle to timely initiation of thrombolytic therapy is delay in referral to the emergency department. Therefore, public education to promote public awareness could be of great benefit in reducing the referral delay time.
similar resources
مقایسه تأثیر وضعیت طاق باز و دمر بر وضعیت تنفسی نوزادان نارس مبتلا به سندرم دیسترس تنفسی حاد تحت درمان با پروتکل Insure
کچ ی هد پ ی ش مز ی هن ه و فد : ساسا د مردنس رد نامرد ي سفنت سرتس ي ظنت نادازون داح ي سکا لدابت م ي و نژ د ي سکا ي د هدوب نبرک تسا طسوت هک کبس اـه ي ناـمرد ي فلتخم ي هلمجزا لکتورپ INSURE ماجنا م ي دوش ا اذل . ي هعلاطم ن فدهاب اقم ي هس عضو ي ت اه ي ندب ي عضو رب رمد و زاب قاط ي سفنت ت ي هـب لاتـبم سراـن نادازون ردنس د م ي سفنت سرتس ي لکتورپ اب نامرد تحت داح INSURE ماجنا درگ ...
full textموانع دریافت فعال کننده پلاسمینوژن بافتی در بیماران مبتلا به سکته مغزی ایسکمیک
سابقه و هدف: سکته مغزی سومین علت مرگ و اولین علت ناتوانی در جهان میباشد. فعالکننده پلاسمینوژن بافتی از درمانهای معدود برای این بیماری است که در حال حاضر در تعداد اندکی از مراکز درمانی در کشور ما مورد استفاده قرار میگیرد. با توجه به عدم استفاده از این دارو در قزوین، این مطالعه بهمنظور تعیین فراوانی افراد مناسب برای دریافت این دارو و عوامل ممانعتکننده از این امر در بیمارستان بوعلی قزوین انج...
full textمقایسه اثربخشی داروی سیتیکولین با دارونما در درمان بیماران مبتلا به سکته مغزی
Background and Objective: Evidence is indicative of the positive effect of citicoline administration in stroke patients; however, there are controversies over this issue. Regarding this, the present study was conducted to investigate the efficacy of citicoline in acute stroke patients. Materials and Methods: This randomized clinical trial was conducted on 160 patients with hemorrhagic and isch...
full textبررسی پیش آگهی یکساله بیماران مبتلا به سکته مغزی
Background and purpose: Stroke is one of the most common causes of death. This study aimed at evaluating the one-year prognosis in patients with stroke. Materials and methods: In this descriptive cross-sectional research, 361 stroke patients admitted in Hamedan Sina Hospital, 2015-2016 were studied. Data were collected using a checklist on demographic characteristics, risk factors, Modified Ra...
full textMy Resources
Journal title
volume 23 issue 102
pages 107- 110
publication date 2013-07
By following a journal you will be notified via email when a new issue of this journal is published.
No Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023